alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS OF RENAL CARE GROUP, INC. FOR THE SIX MONTHS ENDED JUNE 30,
1998, AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>
<CURRENCY> U.S. DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               JUN-30-1998
<EXCHANGE-RATE>                                      1
<CASH>                                          16,026
<SECURITIES>                                         0
<RECEIVABLES>                                   68,869
<ALLOWANCES>                                         0
<INVENTORY>                                      5,618
<CURRENT-ASSETS>                                96,797
<PP&E>                                          71,716
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                 330,640
<CURRENT-LIABILITIES>                           58,058
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           269
<OTHER-SE>                                     196,739
<TOTAL-LIABILITY-AND-EQUITY>                   330,640
<SALES>                                        169,973
<TOTAL-REVENUES>                               169,973
<CGS>                                          112,723
<TOTAL-COSTS>                                  112,723
<OTHER-EXPENSES>                                27,058
<LOSS-PROVISION>                                 4,420
<INTEREST-EXPENSE>                               1,342
<INCOME-PRETAX>                                 24,430
<INCOME-TAX>                                     9,039
<INCOME-CONTINUING>                             15,391
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    15,391
<EPS-PRIMARY>                                      .58
<EPS-DILUTED>                                      .55
        

</TABLE>
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM SUPERGEN,
INC. SEPTEMBER 30, 1999 CONSOLIDATED FINANCIAL STATEMENTS AND IS QUALIFIED IN
ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               SEP-30-1999
<CASH>                                          31,844
<SECURITIES>                                     1,042
<RECEIVABLES>                                      980
<ALLOWANCES>                                        10
<INVENTORY>                                      1,631
<CURRENT-ASSETS>                                37,865
<PP&E>                                           4,009
<DEPRECIATION>                                   1,193
<TOTAL-ASSETS>                                  46,762
<CURRENT-LIABILITIES>                            3,231
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       128,802
<OTHER-SE>                                       (998)
<TOTAL-LIABILITY-AND-EQUITY>                    46,762
<SALES>                                          3,076
<TOTAL-REVENUES>                                 3,076
<CGS>                                            1,324
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                30,657
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                               (28,380)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (28,380)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (28,380)
<EPS-BASIC>                                     (1.29)
<EPS-DILUTED>                                   (1.29)


</TABLE>
**Exhibit 32.1**

**CERTIFICATION PURSUANT TO**

**SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE,**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of PointTherapeutics, Inc. (“Point”) for the three month period ended March 31, 2006 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Donald R. Kiepert, Jr., Chief ExecutiveOfficer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge: 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and 

(2) The information contained in the Report fairly presents, in all material respects, the financial conditions and results of operations of Point.

Dated: May 10, 2006 

 

In connection with the Quarterly Report on Form 10-Q of Point Therapeutics, Inc.(“Point”) for the three month period ended March 31, 2006 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Richard N. Small, Chief Financial Officer of the Company, certify, pursuantto 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge: 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and 

(2) The information contained in the Report fairly presents, in all material respects, the financial conditions and results of operations of Point. 

Dated: May 10, 2006 

 

A signed original of these written statements required by Section 906 has been providedto Point Therapeutics, Inc. and will be retained by Point Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
---

Exhibit 13.2

Certifications of the CEO AND CFOPursuant to Section 906 of the Sarbanes-Oxley Act of
2002

In connection with the Annual Report of Merus Labs
International Inc. (the Company) on Form 20-F/A for the year ended September
30, 2013, as filed with the Securities and Exchange Commission on the date
hereof (the Report), Andrew Patient hereby certifies, pursuant to 18 U.S.C.
ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, to
the best of his or her knowledge, that:

| | (1) | the Report fully complies with the requirements of
      section 13(a) or 15(d) of the Securities Exchange Act of 1934;
  and                                  
| | --- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------
| |     |                                                                                                                                                                
| | (2) | the information contained in the Report fairly presents,
      in all material respects, the financial condition and result of operations
      of the Company.



Date: January 7, 2014

|By: | /s/ ANDREW PATIENT                          
|--- | --------------------------------------------
|    | Name:      Andrew
      Patient             
|    | Title:         Chief
      Financial Officer

This certification accompanies the Report pursuant to s. 906 of
the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by
the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of
ss. 18 of the Securities Exchange Act of 1934, as amended.

---
Exhibit 32

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of American Soil Technology, Inc. (the
"Company") on Form 10-K as amended, for the fiscal year ending September 30,
2015 as filed with the Securities and Exchange Commission on the date hereof
(the "Report"), I, Carl P. Ranno, Chief Executive Officer, President, and Chief
Financial Officer of the Company, certify, pursuant to 18 U.S.C. ss.1350, as
adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002, that:

     1.   The Report fully complies with the requirements of section 13(a) or
          15(d) of the Securities Exchange Act of 1934; and

     2.   The information contained in the Report fairly presents, in all
          material respects, the financial condition and results of operations
          of the Company.


/s/ Carl P. Ranno
----------------------------------
Carl P. Ranno
Chief Executive Officer, President
and Chief Financial Officer
September 19, 2016
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Commodity Futures Trading Commission

# TIME AND DATE: 

11 a.m., Friday, October 22, 2010.

# PLACE:

1155 21st St., NW., Washington, DC, 9th Floor Commission Conference Room.

# STATUS:

Closed.

# MATTERS TO BE CONSIDERED:

Surveillance and Enforcement Matters.

# CONTACT PERSON FOR MORE INFORMATION:

Sauntia S. Warfield, 202-418-5084.

Sauntia S. Warfield,

Assistant Secretary of the Commission.

[FR Doc. 2010-23649 Filed 9-17-10; 4:15 pm]

BILLING CODE 6351-01-P
```

[Congressional Record Volume 141, Number 81 (Tuesday, May 16, 1995)]
[House]
[Page H4965]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

                        REPUBLICANS AND MEDICARE

  (Ms. DeLAURO asked and was given permission to address the House for 
1 minute and to revise and extend her remarks.)
  Ms. DeLAURO. Mr. Speaker, the public is not fooled by the Republican 
shell game.
  They oppose Republican plans to pay for a tax break for the 
privileged few by cutting Medicare.
  Today's Washington Post tells us that 56 percent of the people are 
opposed to the Republican plan to cut Medicare. They are not fooled by 
Republican claims of fixing Medicare. The public is on to the 
Republican scam of using Medicare as a piggy bank to pay for their tax 
breaks for the privileged few.
  Rather than wiping out billions of dollars in tax cuts for large 
corporations, Republicans chose to slash support for the old and the 
sick.
  The Republican chairman of the House Ways and Means Committee says he 
will not touch the billions of dollars of tax breaks for wealthy 
corporate special interests.
  Mr. Speaker, let us go after the billions in corporate tax breaks 
before we stick a ``sick tax'' on our parents and grandparents.

                          ____________________
```
September 12, 1979.

422 A.2d 1166

#### Commonwealth v. Gaydos, Appellant.

Submitted April 12, 1979.

Lester G. Nauhaus, for appellant; Robert L. Eberhardt, Assistant District Attorney, for Commonwealth, appellee.

Before CERCONE, P. J., and WIEAND and HOFFMAN, JJ.

Order and judgment of sentence affirmed.

CERCONE, P. J., concurred in the result.
[DO NOT PUBLISH]

In the

United States Court of Appeals

For the Eleventh Circuit

____________________

No. 19-11257

Non-Argument Calendar

____________________

UNITED STATES OF AMERICA, 

Plaintiff-Appellee,

versus

BOBBY LEE INGRAM, 

Defendant-Appellant.

____________________

Appeal from the United States District Court

for the Southern District of Georgia

D.C. Docket No. 5:94-cr-00002-WTM-BWC-2

____________________

USCA11 Case: 19-11257 Document: 64-1 Date Filed: 05/17/2023 Page: 1 of 3
2 Opinion of the Court 19-11257

ON REMAND FROM THE

SUPREME COURT OF THE UNITED STATES

Before GRANT, LUCK, and EDMONDSON, Circuit Judges.

PER CURIAM:

In this appeal, we originally affirmed in part and vacated in 

part the district court’s order denying Bobby Lee Ingram’s motion 

for a sentence reduction under section 404 of the First Step Act 

2018. See United States v. Ingram, 831 F. App’x 454 (11th Cir. 2020) 

(unpublished). In pertinent part,

* we concluded -- based on our 

decision in United States v. Jones, 962 F.3d 1290 (11th Cir. 2020) --

that the district court was bound by its earlier judge-made finding 

that Ingram was responsible for 4,167 grams of crack cocaine. 

Given that drug-quantity finding, we concluded that a “sentence of 

life imprisonment [was] still the lowest possible penalty that would 

be available to [Ingram] under the Fair Sentencing Act.” The district court thus lacked authority to reduce Ingram’s sentence for 

Count 1. See Ingram, 831 F. App’x at 458. 

* Because we found the record ambiguous about whether the district court 

understood properly the scope of its authority to reduce Ingram’s sentence on 

Count 14, we vacated in part the district court’s denial and remanded for further proceedings. That portion of our decision is not at issue now.

USCA11 Case: 19-11257 Document: 64-1 Date Filed: 05/17/2023 Page: 2 of 3
19-11257 Opinion of the Court 3

The Supreme Court later granted certiorari, vacated our decision, and remanded the case to us for additional consideration in 

the light of its decision in Concepcion v. United States, 142 S. Ct. 

2389 (2022). See Ingram v. United States, 143 S. Ct. 70 (2022). 

We have since concluded that the Supreme Court’s decision 

in Concepcion did not abrogate the reasoning of our decision in 

Jones, including our determination that “the district court is bound 

by a previous finding of drug quantity that could have been used 

to determine the movant’s statutory penalty at the time of sentence.” See United States v. Jackson, 58 F.4th 1331, 2023 U.S. App. 

LEXIS 2772 *1, *8-9 (11th Cir. 2023) (reinstating the Court’s prior 

decision affirming the denial of Jackson’s motion to reduce his sentence). 

Because our decision in Jones remains binding law, we reinstate our prior decision in this appeal.

OPINION REINSTATED; AFFIRMED IN PART, 

VACATED IN PART, AND REMANDED.

USCA11 Case: 19-11257 Document: 64-1 Date Filed: 05/17/2023 Page: 3 of 3
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          SEP-30-1999
<PERIOD-START>                             OCT-01-1998
<PERIOD-END>                               SEP-30-1999
<CASH>                                       2,121,753
<SECURITIES>                                         0
<RECEIVABLES>                                  692,641
<ALLOWANCES>                                  (15,609)
<INVENTORY>                                    534,467
<CURRENT-ASSETS>                             2,798,786
<PP&E>                                         240,024
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                               3,473,831
<CURRENT-LIABILITIES>                          949,160
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         4,403
<OTHER-SE>                                   2,836,805
<TOTAL-LIABILITY-AND-EQUITY>                 3,785,965
<SALES>                                      1,836,142
<TOTAL-REVENUES>                             1,836,142
<CGS>                                        1,721,029
<TOTAL-COSTS>                                1,721,029
<OTHER-EXPENSES>                             3,335,907
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   2
<INCOME-PRETAX>                            (3,123,284)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (3,123,284)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (3,123,824)
<EPS-BASIC>                                     (1.11)
<EPS-DILUTED>                                   (1.11)


</TABLE>
```

[Congressional Record Volume 141, Number 86 (Tuesday, May 23, 1995)]
[House]
[Page H5470]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

                              ADJOURNMENT

  Mr. SMITH of Michigan. Mr. Speaker, I move that the House do now 
adjourn.
  The motion was agreed to; accordingly (at 7 o'clock and 7 minutes 
p.m.), the House adjourned until Wednesday, May 24, 1995, at 10 a.m.

                          ____________________
```
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 21-2093

DONAT CALEB PORTER,

Plaintiff - Appellant,

v.

MERRICK B. GARLAND, Attorney General; JOSHUA STEIN, Attorney General 

of North Carolina; ROXANN H. VANEEKHOVEN; JENNIFER M. TAYLOR; 

CASEY E. WALLACE; MARTIN B. MCGEE; DAVID BRENT CLONINGER; 

BENJAMIN G. GOFF; VAN SHAW; DAVID BRADSON RILEY; JOSH W. 

HELMS; JAMES N. BAILEY; KEVIN PFISTER; DUSTIN GROOMS; JAMES 

ROMINGER; CITY OF CONCORD,

Defendants - Appellees.

Appeal from the United States District Court for the Middle District of North Carolina, at 

Greensboro. Loretta C. Biggs, District Judge. (1:20-cv-00573-LCB-JEP)

Submitted: March 23, 2022 Decided: July 28, 2022

Before GREGORY, Chief Judge, AGEE, Circuit Judge, and TRAXLER, Senior Circuit 

Judge.

Affirmed by unpublished per curiam opinion.

Donat Caleb Porter, Appellant Pro Se. Richard Martin Koch, LAW OFFICES OF 

RICHARD M. KOCH, PA, Charlotte, North Carolina; Steven Andrew Bader, Raleigh, 

North Carolina, Patrick Houghton Flanagan, CRANFILL SUMNER, LLP, Charlotte, 

USCA4 Appeal: 21-2093 Doc: 17 Filed: 07/28/2022 Pg: 1 of 3
2

North Carolina, for Appellees.

Unpublished opinions are not binding precedent in this circuit.

USCA4 Appeal: 21-2093 Doc: 17 Filed: 07/28/2022 Pg: 2 of 3
3

PER CURIAM:

Donat Caleb Porter appeals the district court’s order and judgment dismissing his 

civil rights complaint. We have reviewed the record and find no reversible error. 

Accordingly, we affirm. Porter v. Garland, No. 1:20-cv-00573-LCB-JEP (M.D.N.C. Aug. 

6, 2021). We dispense with oral argument because the facts and legal contentions are 

adequately presented in the materials before this court and argument would not aid the 

decisional process.

AFFIRMED

USCA4 Appeal: 21-2093 Doc: 17 Filed: 07/28/2022 Pg: 3 of 3
Exhibit 21.1


Subsidiaries of Franklin Street Properties Corp.


                                                            Jurisdiction of
Name                                                        Organization
----                                                        ------------

FSP Investments LLC                                         Massachusetts
FSP Holdings LLC                                            Delaware
FSP REIT Protective Trust                                   Massachusetts
FSP Protective TRS Corp.                                    Massachusetts
FSP Property Management LLC                                 Massachusetts
FSP Merrywood Apartments Limited Partnership                Texas
FSP North Andover Office Park Limited Partnership           Massachusetts
FSP Park Seneca Limited Partnership                         Massachusetts
FSP Piedmont Center Limited Partnership                     Massachusetts
FSP Hillview Center Limited Partnership                     Massachusetts
FSP Forest Park IV NC Limited Partnership                   North Carolina
FSP Southfield Centre Limited Partnership                   Massachusetts
FSP Austin N.W. Limited Partnership                         Massachusetts
FSP Lyberty Way Limited Partnership                         Massachusetts
FSP Willow Bend Office Center Corp.                         Delaware
FSP Park Ten Limited Partnership                            Texas
FSP Montague Business Center Corp.                          Delaware
FSP Addison Circle Corp.                                    Delaware
FSP Royal Ridge Corp.                                       Delaware
FSP Collins Crossing Corp.                                  Delaware
FSP Innsbrook Corp.                                         Delaware
FSP 380 Interlocken Corp.                                   Delaware
FSP Blue Lagoon Drive Corp.                                 Delaware
FSP Eldridge Green Corp.                                    Delaware
FSP Greenwood Plaza Corp.                                   Delaware
FSP River Crossing LLC                                      Delaware
FSP River Crossing Corp.                                    Delaware
FSP Liberty Plaza Limited Partnership                       Texas
FSP One Overton Park LLC                                    Delaware
FSP 390 Interlocken LLC                                     Delaware
FSP Goldentop Technology Center Limited Partnership         California
FSP Bollman Place Limited Partnership                       Massachusetts